2000
DOI: 10.1097/00002371-200009000-00007
|View full text |Cite
|
Sign up to set email alerts
|

Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer

Abstract: Polymorphic epithelial mucin, encoded by the MUC1 gene, is present at the apical surface of glandular epithelial cells. It is over-expressed and aberrantly glycosylated in most breast tumors, resulting in an antigenically distinct molecule and a potential target for immunotherapy. This transmembrane protein, when produced by tumor cells, is often cleaved into the circulation, where it is detectable as a tumor marker (CA 15.3) by various antibodies, allowing for early detection of recurrences and evaluation of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
57
0

Year Published

2002
2002
2022
2022

Publication Types

Select...
6
4

Relationship

1
9

Authors

Journals

citations
Cited by 114 publications
(60 citation statements)
references
References 13 publications
3
57
0
Order By: Relevance
“…A synthetic MUC1 peptide vaccine in a liposomal formulation was shown to prolong survival of the patients with non-small cell lung cancer [6]. Vaccinia viruses that express both MUC1 VNTR and IL-2 were shown to induce MUC1-specific antibodies and CTL in some of the patients with advanced inoperable breast cancer [7]. MUC1 coupled with keyhole limpet hemocyanin (KLH) + QS-21 (a potent adjuvant) was demonstrated to induce MUC-1-specific antibody but only a minimal T cell response in clinical trials [8][9][10].…”
Section: Introductionmentioning
confidence: 99%
“…A synthetic MUC1 peptide vaccine in a liposomal formulation was shown to prolong survival of the patients with non-small cell lung cancer [6]. Vaccinia viruses that express both MUC1 VNTR and IL-2 were shown to induce MUC1-specific antibodies and CTL in some of the patients with advanced inoperable breast cancer [7]. MUC1 coupled with keyhole limpet hemocyanin (KLH) + QS-21 (a potent adjuvant) was demonstrated to induce MUC-1-specific antibody but only a minimal T cell response in clinical trials [8][9][10].…”
Section: Introductionmentioning
confidence: 99%
“…T-Cell immunity is thought to be a major driving force in the rejection of tumor cells (25). Indeed, many tumor vaccination models, including those aimed at using the MUC1 antigen, attempt to specifically invoke Th1 immunity in the hopes of generating tumor-specific T cells (12,30,31). It is clear that DA-3/sec cells elicit T-cell immunity; however, what role the MUC1/ sec-derived peptide plays in the generation of Th1 immunity is still unclear.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, only MUC1 expressed endogenously, as would be the case for DNA-based immunogens, will be processed to produce a peptide from the signal sequence. Including a DNA-based formulation such as recombinant vaccinia expressing MUC1 that has been tested recently, 36 or naked cDNA (clinical study initiated), may therefore be important. The requirement for a prime boost type protocol for induction of MUC1 specific CTL detectable in vitro also suggests that combinations of different formulations of MUC1 should be evaluated.…”
Section: Discussionmentioning
confidence: 99%